Phase 1b combination study of Tazemetostat with Tecentriq (atezolizumab) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Trial Profile

Phase 1b combination study of Tazemetostat with Tecentriq (atezolizumab) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Tazemetostat (Primary) ; Atezolizumab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Proof of concept
  • Sponsors Genentech
  • Most Recent Events

    • 09 Mar 2017 According to an Epizyme media release, company expects the optimal dose will be established this year.
    • 03 Nov 2016 According to an Epizyme media release, status changed from planning to recruiting.
    • 22 Jun 2016 According to Epizyme media release, company plans to enroll patients in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top